Literature DB >> 6690069

New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties.

F M Sirotnak, J I DeGraw, D M Moccio, L L Samuels, L J Goutas.   

Abstract

Structural modification of the N10 position of 4-amino folates affects mediated membrane transport in mammalian cells but has little or no effect on target enzyme (dihydrofolate reductase) inhibition. Some of these modifications have been associated with differential effects on transport in various cell types in a manner which favored greater accumulation and persistence of drug in responsive tumor cells than in normal proliferative tissue. With the aid of identifying new structures with greater potential for differential mediated accumulation, we have studied three new 10-alkyl analogs of 10-deaza-aminopterin. Two of these analogs showed therapeutic efficacy substantially greater than 10-deaza-aminopterin, an analog with antitumor properties superior to methotrexate. These analogs, the 10-methyl, 10-ethyl, and 10,10-dimethyl derivatives, were equivalent to the parent compound, 10-deaza-aminopterin, and aminopterin, and slightly more potent than methotrexate, as inhibitors of L1210 cell dihydrofolate reductase. The three new analogs, 10-deaza-aminopterin, and aminopterin exhibited similar transport properties in L1210, Ehrlich, and S180 cells. Efflux and influx Vmax were similar to those of methotrexate, but influx Km was 4- to 14-fold lower than for methotrexate. That is, substitution at N10, but not at C10, reduced influx potential in these tumor cells. These differences in transport properties among this group of analogs which determine net accumulation were reflected in the individual values for growth-inhibitory potency. In contrast to that seen in tumor cells, alkylation at both N10 and C10 reduced influx potential (increased Km) in isolated intestinal epithelial cells from mouse small intestine. Influx was in the order aminopterin greater than 10-deaza-aminopterin with further reduction in each series showing a magnitude in proportion to the size of the 10 substituent. Otherwise, influx Vmax and efflux were similar for the group. Accumulation of polyglutamates in small intestine was greater following aminopterin administration than following administration of other analogs (10-ethyl, 10-deaza-aminopterin less than methotrexate less than 10-deaza-aminopterin). Polyglutamate accumulation for all the analogs was greater in tumor cells, but accumulation of each varied between the two tumors (L1210 and S180) examined. Differences among the analogs were not as great in L1210 as in S180 cells, and their metabolism was not in the same relative order.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690069     DOI: 10.1007/bf00255903

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors.

Authors:  F M Sirotnak; R C Donsback
Journal:  Cancer Res       Date:  1975-07       Impact factor: 12.701

2.  Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells.

Authors:  P L Chello; F M Sirotnak; D M Dorick; R C Donsbach
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

3.  Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.

Authors:  F M Sirotnak; R C Donsbach
Journal:  Cancer Res       Date:  1973-06       Impact factor: 12.701

4.  The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic acid reductase and of DNA synthesis.

Authors:  S Margolis; F S Philips; S S Sternberg
Journal:  Cancer Res       Date:  1971-12       Impact factor: 12.701

5.  Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate-resistant murine tumors to the lipophilic antifolate, metoprine.

Authors:  F M Sirotnak; D M Moccio; L J Goutas; L E Kelleher; J A Montgomery
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

6.  Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.

Authors:  F M Sirotnak; J I DeGraw; P L Chello; D M Moccio; D M Dorick
Journal:  Cancer Treat Rep       Date:  1982-02

7.  New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.

Authors:  F M Sirotnak; J I DeGraw; F A Schmid; L J Goutas; D M Moccio
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin.

Authors:  J I DeGraw; V H Brown; H Tagawa; R L Kisliuk; Y Gaumont; F M Sirotnak
Journal:  J Med Chem       Date:  1982-10       Impact factor: 7.446

9.  Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissues in vivo.

Authors:  R G Poser; F M Sirotnak; P L Chello
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

10.  Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice.

Authors:  F M Sirotnak; J I DeGraw; D M Moccio; D M Dorick
Journal:  Cancer Treat Rep       Date:  1978-07
View more
  31 in total

Review 1.  Targeted treatment and new agents in peripheral T-cell lymphoma.

Authors:  Jasmine M Zain; Owen O'Connor
Journal:  Int J Hematol       Date:  2010-06-10       Impact factor: 2.490

2.  Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy.

Authors:  J S Lee; W K Murphy; M H Shirinian; A Pang; W K Hong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Novel therapies for peripheral T-cell lymphomas.

Authors:  Andrei Shustov
Journal:  Ther Adv Hematol       Date:  2013-06

Review 4.  Folate, antifolates, and folate analogs in pediatric oncology.

Authors:  M C Hum; B A Kamen
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  Promising new agents in the treatment of non-small cell lung cancer.

Authors:  M J Edelman; D R Gandara
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Phase II trial of edatrexate in patients with metastatic colorectal cancer.

Authors:  G H Clamon; C E Riggs; R Dreicer; R J Hohl
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models.

Authors:  F M Sirotnak; J I DeGraw; F A Schmid; L J Goutas; D M Moccio
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 8.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

9.  Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Authors:  Enrica Marchi; Owen A O'Connor
Journal:  Ther Adv Hematol       Date:  2012-08

10.  Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.

Authors:  E Izbicka; A Diaz; R Streeper; M Wick; D Campos; R Steffen; M Saunders
Journal:  Cancer Chemother Pharmacol       Date:  2009-02-17       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.